戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nced susceptibility to C. rodentium-enhanced infectious colitis.
2 as in Crohn disease, ulcerative colitis, and infectious colitis.
3  and against colonic pathology in a model of infectious colitis.
4 te to stressor-enhanced C. rodentium-induced infectious colitis.
5 ness and treat disease in an animal model of infectious colitis.
6 . coli in chemical and genetic models of non-infectious colitis.
7 or evaluation and treatment of patients with infectious colitis.
8 culture should be performed in patients with infectious colitis.
9 ogy, pathobiology, and mechanisms underlying infectious colitis.
10 t advances in knowledge of pathogens causing infectious colitis.
11 novel strategies for preventing and treating infectious colitis.
12 between bacteria and fungi in the gut during infectious colitis.
13  of the gut microbiota in the context of non-infectious colitis.
14 red susceptibility to chemically induced and infectious colitis.
15 in the Citrobacter rodentium model of murine infectious colitis.
16 for improving intestinal barrier function in infectious colitis.
17 n as a type III secretion system, leading to infectious colitis and inflammation.
18 mpromised in inflammatory conditions such as infectious colitis and inflammatory bowel disease (IBD).
19 hown to be associated with susceptibility to infectious colitis and liver abscess due to Entamoeba hi
20 r rodentium model mimics the pathogenesis of infectious colitis and requires sequential contributions
21 , Crohn's disease, irritable bowel syndrome, infectious colitis, and microscopic colitis, as well as
22 rotective cytokines and confer protection in infectious colitis, and their cell numbers in the colon
23 talin-1 plays a role in the manifestation of infectious colitis by increasing mucosal macrophages, wi
24 ucTn-seq to C. rodentium in a mouse model of infectious colitis bypassed a highly restrictive host bo
25 enders mice susceptible to a more aggressive infectious colitis caused by Citrobacter rodentium.
26                  No patient had identifiable infectious colitis, colonic stricture, bowel obstruction
27 estinal infections continues to increase and infectious colitis contributes to significant morbidity
28 e with cancer but in none of the ischemic or infectious colitis controls (P<0.03).
29           The role of innate immune cells in infectious colitis, however, is less well understood.
30  significantly enhanced C. rodentium-induced infectious colitis in resistant mice, as measured by inc
31 eveloping a common macaques disease outcome (infectious colitis) in 170 socially-housed rhesus monkey
32                           Also patients with infectious colitis, in particular Salmonella and Campylo
33                                              Infectious colitis is diagnosed in someone with diarrhea
34  not reduce all aspects of stressor-enhanced infectious colitis, it did significantly reduce pathogen
35 ammatory bowel disease (IBD) and Non-IBD/Non-Infectious Colitis (NIC).
36 therapy should be initiated for all forms of infectious colitis other than STEC.
37 dium difficile remains an important cause of infectious colitis, particularly in healthcare facilitie
38 ly DUOX2, and alleviated both chemically and infectious colitis severity.
39  EC has also been reported in the setting of infectious colitis suggesting an alternate etiology.
40 t; one patient receiving sorafenib died from infectious colitis while on treatment and four patients